246 related articles for article (PubMed ID: 7564839)
1. A murine model for the immunotherapy of head and neck squamous cell carcinoma.
Hier MP; Black MJ; Shenouda G; Sadeghi N; Karp SE
Laryngoscope; 1995 Oct; 105(10):1077-80. PubMed ID: 7564839
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
[TBL] [Abstract][Full Text] [Related]
3. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma.
Sadeghi N; Black MJ; Hier MP; Shenouda G; Karp SE
Arch Otolaryngol Head Neck Surg; 1997 Jan; 123(1):25-30. PubMed ID: 9006500
[TBL] [Abstract][Full Text] [Related]
4. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
Duan DS
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
[TBL] [Abstract][Full Text] [Related]
5. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
6. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
7. [Interleukin-2 and LAK cells in the local immunotherapy of tumors of the head and neck: an experimental model].
Sacchi M; Johnson JT; Whiteside TL; Cortesina G
Acta Otorhinolaryngol Ital; 1989; 9(4):391-8. PubMed ID: 2618654
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with dendritic cells in an animal model of early pulmonary metastatic squamous cell carcinoma.
Moon JH; Chung MK; Son YI
Laryngoscope; 2012 Nov; 122(11):2442-6. PubMed ID: 22926978
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor activity of adherent LAK cells (A-LAK) in a model of squamous carcinoma of the head and neck].
Sacchi M; Galeazzi E; Johnson JT; Cavalot AL; Cortesina G
Acta Otorhinolaryngol Ital; 1991; 11(4):405-15. PubMed ID: 1792895
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
[TBL] [Abstract][Full Text] [Related]
11. Effect of combined adoptive immunotherapy and radiotherapy on tumor growth.
Sumareva R; Ukrainsky G; Kiremidjian-Schumacher L; Roy M; Wishe HI; Steinfeld AD; Cooper JS
Radiat Oncol Investig; 1999; 7(1):22-9. PubMed ID: 10030620
[TBL] [Abstract][Full Text] [Related]
12. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
13. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
[TBL] [Abstract][Full Text] [Related]
14. Combination nonviral cytokine gene therapy for head and neck cancer.
Li D; Zeiders JW; Liu S; Guo M; Xu Y; Bishop JS; O'Malley BW
Laryngoscope; 2001 May; 111(5):815-20. PubMed ID: 11368072
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy.
Khurana D; Martin EA; Kasperbauer JL; O'Malley BW; Salomao DR; Chen L; Strome SE
Head Neck; 2001 Oct; 23(10):899-906. PubMed ID: 11592238
[TBL] [Abstract][Full Text] [Related]
16. Enhanced local dendritic cell activity and tumor-specific immunoresponse in combined radiofrequency ablation and interleukin-2 for the treatment of human head and neck cancer in a murine orthotopic model.
Saito K; Araki K; Reddy N; Guang W; O'Malley BW; Li D
Head Neck; 2011 Mar; 33(3):359-67. PubMed ID: 20652887
[TBL] [Abstract][Full Text] [Related]
17. Generation of an autologous cell system for immunotherapy of squamous cell carcinoma of the head and neck.
Mayer A; Andratschke M; Pauli C; Graefe H; Kristina K; Wollenberg B
Anticancer Res; 2005; 25(6B):4075-80. PubMed ID: 16309201
[TBL] [Abstract][Full Text] [Related]
18. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer.
Whiteside TL; Chikamatsu K; Nagashima S; Okada K
Anticancer Res; 1996; 16(4C):2357-64. PubMed ID: 8816835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]